ReviewPain reports2025
Fibromyalgia: do I tackle you with complementary medicines?
Review in Pain reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent guidelines for managing fibromyalgia highlight the importance of a graded-care approach, tailoring treatment to predominant symptoms, and appropriately integrating nonpharmacological treatments and complementary medicine (CM). Many fibromyalgia patients turn to nonpharmacological treatment and CM for various reasons, including concerns about medication side effects and persistent symptoms despite pharmacological treatment. In addition, these approaches are sometimes mistakenly, but often, perceived as natural and, therefore, widely accepted as well-tolerated with minimal risks. However, as with many patients using CM, fibromyalgia patients frequently engage in these practices without informing their physicians, often because of fear of a negative reaction. This can occur in contexts that lack adequate safeguards, such as treatment by noncertified practitioners, undocumented practices, excessive costs, or unsafe environments. In this narrative review, we first provide updated definitions of these practices, discuss their potential benefits and associated risks, and explore the challenges in their evaluation. We then summarize key findings from the literature before proposing a structured approach for discussing these practices with fibromyalgia patients. This includes assessing their prior experiences, expectations, and motivations for long-term adherence. We also offer guidance on selecting qualified practitioners and ensuring a sufficiently safe treatment environment. Finally, we highlight essential "red flags" that pain specialists and health care providers should discuss with patients, emphasizing the need for caution or even discontinuation of certain practices when these warning signs are present.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.